NASDAQ: ONTX was devalued by Zacks Research from a “purchase” score to a “hold” ranking in a research note released to capitalists on Thursday, Zacks.com records.
According to Zacks, “Onconova Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm. It focuses on discovering and also establishing tiny molecule drug prospects to deal with cancer. The Firm‘s items under different phases of growth consist of Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 and also Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. “
Several other equities research analysts likewise lately discussed the business. Noble Financial reissued a “acquire” ranking as well as provided a $11.00 cost objective on shares of Onconova Therapeutics in a report on Thursday, September 23rd. Guggenheim dropped their price target on Onconova Therapeutics from $29.00 to $12.00 and also established a “acquire” rating on the stock in a research note on Tuesday, September 28th.
NASDAQ: ONTX opened up at $2.25 on Thursday. Onconova Therapeutics has a twelve month low of $2.22 as well as a twelve month high of $28.95. Business has a 50 day moving ordinary price of $2.90 as well as a two-hundred day moving typical price of $4.16. The business has a market cap of $46.76 million, a P/E proportion of -1.82 as well as a beta of 1.67.
Onconova Therapeutics (NASDAQ: ONTX) last launched its quarterly revenues results on Thursday, November 11th. The biopharmaceutical business reported ($ 0.22) revenues per share for the quarter, topping analysts’ consensus quotes of ($ 0.33) by $0.11. Onconova Therapeutics had a negative return on equity of 59.78% and a negative web margin of 8,294.27%. The firm had revenue of $0.06 million throughout the quarter, contrasted to the agreement price quote of $0.06 million. Throughout the very same quarter in the previous year, the firm published ($ 0.45) EPS. As a group, research experts anticipate that Onconova Therapeutics will certainly post -1.18 EPS for the current year.
A variety of hedge funds have actually recently dealt shares of ONTX. GSA Funding Allies LLP purchased a brand-new setting in Onconova Therapeutics throughout the third quarter worth $922,000. Hudson Bay Capital Monitoring LP bought a new placement in shares of Onconova Therapeutics in the third quarter worth $635,000. Pura Vida Investments LLC got a brand-new position in shares of Onconova Therapeutics in the third quarter worth $575,000. CVI Holdings LLC got a new position in shares of Onconova Therapeutics in the third quarter worth $493,000. Ultimately, Dimensional Fund Advisors LP purchased a brand-new placement in shares of Onconova Therapeutics in the 2nd quarter worth $509,000. Hedge funds and also various other institutional capitalists have 13.36% of the company’s stock.
About Onconova Therapeutics
Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical firm, which takes part in the identification as well as advancement of oncology therapeutics. It focuses on discovering and also creating small particle drug candidates to deal with cancer cells. The firm was founded by Ramesh Kumar and also E. Premkumar Reddy on December 22, 1998 and is headquartered in Newtown, PA
. Obtain a free copy of the Zacks research record on Onconova Therapeutics (ONTX).
To learn more regarding research offerings from Zacks Investment Research, browse through Zacks.com.
This immediate news alert was generated by narrative scientific research innovation and also economic data from Market in order to offer visitors with the fastest as well as most precise coverage. This tale was reviewed by Market’s editorial group before publication.
SHOULD YOU INVEST $1,000 IN ONCONOVA THERAPEUTICS NOW?
Prior to you take into consideration Onconova Therapeutics, you’ll wish to hear this.
Market tracks Wall Street’s top-rated and best performing research analysts and also the stocks they suggest to their customers every day. Market has recognized the five stocks that top analysts are quietly whispering to their clients to purchase currently prior to the broader market catches on … as well as Onconova Therapeutics wasn’t on the listing.
While Onconova Therapeutics presently has a “Buy” rating amongst analysts, top-rated analysts believe these five stocks are better purchases.
